Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$13.64
+0.1%
$12.47
$8.04
$25.88
$373.73M2.27421,186 shs172,653 shs
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
$33.99
$33.89
$17.00
$39.30
$1.63B2.59940,325 shsN/A
Indivior PLC stock logo
INVVY
Indivior
$21.85
-1.8%
$21.85
$14.76
$35.50
$3.01B0.353,825 shs8,100 shs
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$0.25
+0.9%
$0.27
$0.17
$0.48
$362.31M-1.122.09 million shs1.33 million shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$11.19
+1.2%
$10.16
$7.44
$11.82
$557.51M-0.02267,774 shs65,540 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%+2.29%+14.48%+49.67%-37.82%
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Indivior PLC stock logo
INVVY
Indivior
0.00%0.00%0.00%0.00%0.00%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.00%+3.54%-0.60%+19.82%-40.41%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%-0.31%+3.85%+32.52%+31.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.7667 of 5 stars
4.62.00.00.03.22.50.6
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/AN/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.0054 of 5 stars
0.01.00.00.00.00.00.0
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.075 of 5 stars
3.30.00.00.02.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.11
Buy$54.00296.04% Upside
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
0.00
N/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
0.00
N/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.00
N/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.67
Moderate Buy$16.6048.41% Upside

Current Analyst Ratings Breakdown

Latest ARCT, TBPH, INVVY, CNST, and NWBO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.00
6/27/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
6/17/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$24.00
5/28/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$32.00
5/14/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.00
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $66.00
4/10/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$152.31M2.43N/AN/A$8.90 per share1.53
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/A$8.63 per shareN/A
Indivior PLC stock logo
INVVY
Indivior
$791M3.81$1.15 per share18.94$1.45 per share15.07
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$1.38M262.54N/AN/A($0.07) per share-3.55
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$65.27M8.57N/AN/A$3.57 per share3.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/A
Indivior PLC stock logo
INVVY
Indivior
$205M$1.0520.8112.00N/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
-$83.78M-$0.07N/AN/A-5,757.57%N/A-303.49%8/7/2025 (Estimated)
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$56.42M-$1.18N/A31.96N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)

Latest ARCT, TBPH, INVVY, CNST, and NWBO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A-$0.01N/A-$0.01N/A$0.38 million
5/12/2025Q1 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million
5/8/2025Q1 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.06
5.64
5.64
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/A
15.39
15.39
Indivior PLC stock logo
INVVY
Indivior
N/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A
0.06
0.06
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
4.77
4.77
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.12 million22.62 millionOptionable
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
15447.92 millionN/ANot Optionable
Indivior PLC stock logo
INVVY
Indivior
800137.88 millionN/ANot Optionable
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
201.46 billion1.33 billionNot Optionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
11050.00 million46.55 millionOptionable

Recent News About These Companies

TBPH Theravance Biopharma, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$13.64 +0.02 (+0.11%)
As of 07/3/2025 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Constellation Pharmaceuticals stock logo

Constellation Pharmaceuticals NASDAQ:CNST

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Indivior stock logo

Indivior OTCMKTS:INVVY

$21.85 -0.40 (-1.82%)
As of 06/9/2023

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Northwest Biotherapeutics stock logo

Northwest Biotherapeutics OTCMKTS:NWBO

$0.25 +0.00 (+0.85%)
As of 07/3/2025 12:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$11.18 +0.14 (+1.22%)
Closing price 07/3/2025 01:21 PM Eastern
Extended Trading
$11.18 0.00 (0.00%)
As of 07/3/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.